---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-036668"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:33:35.691712+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# INmune Bio raises $9.7M in registered direct offering of common stock and warrants

## Summary
- Offering comprises 986,000 shares and warrants at $9.84 per unit; gross proceeds ~$9.7M.
- Warrants have acceleration clause upon positive Phase 2 Alzheimer's top-line data (XPro1595).
- Closing expected on or about April 29, 2024; Maxim Group LLC is sole placement agent.
- Net proceeds to fund Phase 2 Alzheimer's trial (AD02) and Phase 1 mCRPC trial (INKmune).
- Shares and warrants issued under effective shelf registration statement (S-3, No. 333-254221).

## SEC filing metadata
- accession: 0001213900-24-036668
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024036668/0001213900-24-036668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024036668/ea0204729-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-036668
- JSON: https://secwatch.observer/filing/0001213900-24-036668.json
- Plain text: https://secwatch.observer/filing/0001213900-24-036668.txt

## Key facts
- Material Agreements
  Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 986,000 shares of common stock and warrants at $9.84 per share, aggregate gross proceeds $9,702,240 (effective 2024-04-24).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Purchasers
  - Value: 986,000 shares of common stock and warrants at $9.84 per share, aggregate gross proceeds $9,702,240
  - Effective: 2024-04-24
  source text: On April 24, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser set forth on the signature page thereto (the “Purchasers) for the purchase and sale of an aggregate of 986,000 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 986,000 shares of its common stock (“Warrants”) in a registered direct offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390024036668/0001213900-24-036668-index.htm
- Material Agreements
  Inmune Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at 6% cash fee of gross proceeds (effective 2024-04-24).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Maxim Group LLC
  - Value: 6% cash fee of gross proceeds
  - Effective: 2024-04-24
  source text: Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 24, 2024, between the Company and Maxim Group LLC (the “Placement Agent”), the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390024036668/0001213900-24-036668-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.